June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Impact of corneal cross-linking on drug penetration in humans
Author Affiliations & Notes
  • Christoph Tappeiner
    Department of Ophthalmology, Inselspital, University Hospital of Bern, Bern, Switzerland
  • Markus Tschopp
    Department of Ophthalmology, Inselspital, University Hospital of Bern, Bern, Switzerland
  • Kaspar Schuerch
    Department of Ophthalmology, Inselspital, University Hospital of Bern, Bern, Switzerland
  • Beatrice Frueh
    Department of Ophthalmology, Inselspital, University Hospital of Bern, Bern, Switzerland
  • Footnotes
    Commercial Relationships Christoph Tappeiner, None; Markus Tschopp, None; Kaspar Schuerch, None; Beatrice Frueh, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5261. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christoph Tappeiner, Markus Tschopp, Kaspar Schuerch, Beatrice Frueh; Impact of corneal cross-linking on drug penetration in humans. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5261.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To analyze the influence of corneal cross-linking (CXL) with ultraviolet-A and riboflavin on drug permeability using topically applied pilocarpine.

 
Methods
 

Keratoconus patients (n=10) undergoing standard CXL procedure with ultraviolet-A (5.4 J/cm2, 30 minutes) and riboflavin on one eye were included in the study. Pupillary diameter measured before and every 3 minutes for 30 minutes after the topical application of one drop of pilocarpine was used as an indirect measure for corneal permeability. Pupillary diameter was measured with an infrared pupillometer device (Colvard, Oasis Glendora, CA) before (baseline) and 4 months after CXL.

 
Results
 

Prior to pilocarpine application no significant difference in pupillary diameter was found before CXL and 4 months later (p>0.05). Mean decrease of pupillary diameter 30 minutes after the application of pilocarpine was significantly higher at baseline compared to 4 months follow-up examination (mean decrease of 4.3 vs. 3.5 mm; p=0.03).

 
Conclusions
 

CXL reduces corneal permeability for pilocarpine in humans.

  
Keywords: 479 cornea: clinical science  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×